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ABSTRACT
Over-expression of folate receptor alpha on cancer cells has been frequently 
exploited for delivery of folate-targeted imaging and therapeutic agents to tumors. 
Because limited information exists on expression of the beta isoform of the folate 
receptor in human cancers (FR-β), we have evaluated the immunohistochemical 
staining pattern of FR-β in 992 tumor sections from 20 different human cancer types 
using a new anti-human FR-β monoclonal antibody. FR-β expression was shown to be 
more pronounced in cells within the stroma, primarily macrophages and macrophage-
like cells than cancer cells in every cancer type studied. Moreover, FR-β expression 
in both cancer and stromal cells was found to be statistically more prominent in 
females than males. A significant positive correlation was also observed between 
FR-β expression on stromal cells and both the stage of the cancer and the presence 
of lymph node metastases. Based on these data we conclude FR-β may constitute a 
good target for specific delivery of therapeutic agents to activated macrophages and 
that accumulation of FR-β positive macrophages in the stroma could serve as a useful 
indicator of a tumor’s metastatic potential.
INTRODUCTION
Folic acid (vitamin B9) is required for one-carbon 
metabolism, which is involved in de novo synthesis of 
nucleotides, methylation of DNA, carboxymethylation 
of G proteins and synthesis of many important metabolic 
intermediates [1]. Folic acid is taken into cells via the 
reduced folate carrier [2], the proton coupled folate 
transporter [3] or one of four isoforms (α, β, γ, δ) of the 
folate receptor (FR) [4]. Although FR’s 104-fold higher 
affinity for folate (Kd ~ 10
-10 M) may render the receptor 
the preferred pathway for uptake of the vitamin when 
folate concentrations are low, the restricted expression of 
FR and its general inaccessibility in normal tissues may 
limit this potential benefit to very few cells [5]. Thus, FR-α 
is expressed primarily on the apical surfaces of epithelial 
cells lining the openings in the lungs, kidneys, mammary 
ducts and choroid plexus, where it only encounters 
folates within the respective lumens [6, 7, 8]. Similarly, 
FR-β has only been reported on activated, but not resting 
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or quiescent myeloid cells (primarily monocytes and 
macrophages) [9, 10, 11], which constitute only a small 
fraction of the total myeloid cell population. FR-γ may be 
secreted in very low quantities into the bloodstream where 
it is difficult to detect [12, 13], and FR-δ has only been 
observed on regulatory T cells and ova [14]. 
In contrast to its limited expression in normal 
tissues, FR-α has been found in many types of cancer, 
including cancers of the ovary, lung, kidney, breast, colon 
and endometrium [15]. Indeed, up to 40% of human 
cancers have been recently estimated to over-express FR-α 
[15]. Thus, FR-α has not only become an established tumor 
cell marker, but it has also been exploited for the selective 
delivery of both imaging and therapeutic agents to each 
of the above malignancies [16, 17, 18]. Not surprisingly, 
six folate-targeted drugs are currently undergoing human 
clinical trials [19, 20, 21, 22], and others are in various 
stages of preclinical development. One folate-vinca 
alkaloid conjugate (EC145) has even advanced to phase 
III clinical trials [22] in combination with its companion 
diagnostic agent, folate-99mTc (EC20) [20].
Largely due to the absence of a commercial 
monoclonal antibody for FR-β, little information exists 
on the expression of FR-β in malignant tissues. While the 
β isoform of the folate receptor has recently been shown 
to be expressed on tumor-associated macrophages [9, 10, 
23], the only reports of FR-β expression on malignant 
cells reveal its presence in myelogenous leukemias [24]; 
i.e. consistent with its expression on the corresponding 
nontransformed cells. In an effort to ascertain the 
expression pattern of FR-β in nonmyelogenous 
malignancies, we have exploited a recently developed 
monoclonal antibody to human FR-β [25] to stain nearly 
1000 human tumor tissue sections from 20 different tumor 
types. We report here that FR-β positive tumor associated 
macrophage-like cells are present in most human cancers 
and that several human malignancies that derive from 
FR-β negative cells also express the β isoform of FR.
RESULTS AND DISCUSSION
Characterization of the biotinylated-m909 
antibody
The specificity of the anti-human FR-β 
human monoclonal antibody m909 has been 
previously established by ELISA, surface plasmon 
resonance, flow cytometry, confocal microscopy and 
immunohistochemistry (IHC) staining in a small tissue 
microarray [11, 23, 25], however its use for IHC staining 
of large tumor microarrays has not been reported. After 
exploring multiple staining protocols, it was found that 
use of biotin-derivatized m909 in combination with 
streptavidin-HRP staining yielded the highest resolution 
images. To ensure that attachment of biotin to m909 
did not compromise selectivity of the antibody for FR-
β, binding of biotinylated-m909 was compared with 
CHO-K1 cells that do not express either FR-α or FR-β 
[26], CHO-K1 cells transfected with a stable human FR-β 
expression vector (herein referred to as CHO-β) and 
KB cells that naturally express high levels of FR-α, but 
not FR-β [27]. For this purpose, all three cell lines were 
incubated with Oregon green labeled folate and analyzed 
via flow cytometry to test for expression of a functional 
folate receptor. As expected, mock infected CHO-K1 
cells did not display any folate-Oregon green binding, 
while both the CHO-β and KB cells showed large shifts in 
fluorescence, indicating binding of the fluorescent folate 
(Figure 1). When these same cell lines were incubated 
with various concentrations of biotinylated-m909 followed 
by PeCy7-labeled Streptavidin, the labeled CHO-K1 and 
the FR-α expressing KB cells were indistinguishable 
from the non-labeled cells, indicating no binding of the 
biotinylated-m909 antibody (Figure 1). In contrast, a dose-
dependent change in fluorescence intensity was observed 
when biotinylated m909 was incubated with FR-β 
expressing CHO-β cells (Figure 1). Taken together, these 
data indicate that biotinylation of m909 has little effect on 
FR-β selectivity.
Biotinylated-m909 immunohistochemistry in 
neoplastic human tissues
To determine FR-β expression in both malignant and 
nonmalignant cells of multiple human cancers, IHC was 
performed with the biotinylated m909 antibody on human 
tumor tissue microarrays from a variety of providers. 
Several representative images are shown in Figure 2 from 
different cancer tissue types. Evaluation of the staining in 
both cancer and stromal cells was performed by trained 
pathologists, and in total 992 tumor specimens were 
analyzed. 
As shown in Table 1 and Figure 3, FR-β expression 
on cancer cells was observed in nearly one quarter of 
all samples, with prominent staining noted primarily 
in malignancies of the lung, liver, skin, kidney and soft 
tissue. No FR-β expression was observed in malignant 
cells of head & neck, prostate and colon cancers. In 
contrast, FR-β expression was evident on stromal cells 
in slightly over half of the cancer sections examined. 
Where closely evaluated by trained pathologists, the FR-β 
positive stromal cells appeared to be macrophages or 
macrophage-like cells. Previous studies using cancer and 
inflamed tissues have shown that FR-β positive cells are 
predominantly monocytes/macrophages [9, 10, 11, 23, 28, 
29].
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Figure 1: Characterization of biotin-labeled m909 on cultured cells. Mock CHO-K1 cells, human FR-β stably-transfected CHO 
cells (CHO-β) or KB cells that naturally express FR-α were incubated with Oregon green labeled folate (100 nM) or serial concentrations of 
biotin-m909 followed by Streptavidin-PeCy7 for quantitation. Fluorescent intensity of individual cells was determined by flow cytometry.
Figure 2: Example IHC images using the FR-β specific m909 antibody in various cancer tissues. 
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FR-β staining intensity and patient correlations
To explore possible correlates of FR-β expression, 
the staining intensity (a crude measure of receptor 
concentration) of a multi-cancer TMA from BioMax was 
evaluated by a trained pathologist and scored on a scale 
of 0 to 3. As shown in SI Figure 1, a highly significant 
difference was apparent in the staining intensities of 
cancer cells versus stromal cells, with stromal cells 
showing a nearly 8-fold greater average intensity than the 
cancer cells (p-value = 1.54 x 10-57). This trend of greater 
staining intensity occurred in nearly all cancers tested 
except malignancies of the skin and soft tissue, where the 
staining intensities were nearly equal (SI Figure 2). Since 
FR expression is highly tissue specific and because most 
normal tissues do not express FR [30], the high levels 
of FR-β found in stromal cells of tumors may at first 
seem unusual. However, recent observations that tumor 
associated macrophages express FR-β [9,10,23] and that 
many tumors accumulate these activated macrophages [9, 
10, 23] argue that this result should have been anticipated. 
Next, the derived staining rankings were examined 
for any relationships with patient pathology data, where 
available, using a t-test, 1-way ANOVA or Spearman 
correlation to determine significance (Figure 4 and SI 
Figures 1-8). As summarized in Figure 4A and 4B, no 
correlations were found between stromal cell staining 
intensity and available patient data. However, for cancer 
cells, a weakly significant correlation was noted between 
staining intensity and lymph node involvement (p-value 
= 0.0323). A general inverse correlation between cancer 
stage and FR-β expression on malignant cells was also 
observed (Figure 4B), but this relationship was not 
statistically significant (p-value = 0.1041). 
FR-β staining percentage and patient correlations
In an effort to identify any pathology correlates 
of the percentage of cells staining positive for FR-β, the 
FR-β positive fractions of both stromal and cancer cells 
was quantified by a trained pathologist using the multi-
cancer TMA from Asterand. As summarized in Figure 
5A, the fraction of cancer cells staining positive for FR-β 
did not correlate with the stage of the cancer, size of the 
primary tumor, involvement of lymph nodes or patient 
age. However, the percentage of positive cancer cells and 
stromal cells were both found to co-vary significantly with 
patient sex (p-value of 0.0001 and 0.00002, respectively) 
when sex specific cancers were removed from the analysis 
(breast and ovarian). Although the promoter for FR-α 
contains an estrogen regulatory element that leads to 
FR-α repression [31, 32], no such regulatory sequence 
has been reported for FR-β, leaving the explanation for 
this dramatic impact of gender on FR-β expression largely 
unanswered.
Unlike cancer cells, FR-β expression on stromal 
Figure 3: Prevalence of FR-β expressing cancer and stromal cells in various human tumor sections. The x-axis shows the 
tissue of origin of the cancer with the number of samples tested in parenthesis. 
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cells correlated positively with cancer stage and the closely 
related category of lymph node involvement (p-values of 
0.0212 and 0.0293, respectively), even though none of 
the groups were significantly different from one another 
(Figure 5B). While the mechanistic underpinnings of this 
correlation still need to be explored, it has been established 
for some time that tumor-associated macrophages greatly 
increase the invasiveness and metastatic potential of 
tumors [33, 34, 35]. Because the tumor associated 
macrophages in this study were strongly FR-β positive, 
as reported previously for melanoma, pancreatic and head 
and neck cancers [9, 10, 23], the correlation with cancer 
stage and lymph node involvement suggests the intriguing 
possibility that FR-β might not only constitute a useful 
indicator of tumor metastatic potential, but may also serve 
as an attractive target for folate-mediated delivery of drugs 
for reprogramming the tumor’s immune environment. 
Figure 4: FR-β staining intensity correlations. IHC was performed on a BioMax multi-cancer tissue microarray using the FR-β 
specific monoclonal antibody m909. The relative staining intensity, graded on a scale of 0 to 3, of positively staining cells within the 
tumor and stroma were determined. A) Statistically significant differences (p-value <0.05) using ANOVA or a t-test and correlations using 
a Spearman correlation (p-value <0.05) between the average FR-β staining intensity and various pathological data are summarized. B) 
Graphs for select FR-β staining intensity and various pathological data (error bars represent SEM) are shown. Lymph node involvement 
was based upon the AJCC/UICC stage - TxNxMx. Additional graphs and data can be found in the Supporting Information. 
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CONCLUSION
Roughly a thousand tumor sections from 20 different 
cancers were stained with a new monoclonal antibody to 
human folate receptor β. Analysis of the stained sections 
indicate that FR-β is more prevalent in stromal cells 
than cancer cells and that expression on stromal cells 
is primarily found on tumor associated macrophages 
and macrophage-like cells. When correlations with 
other patient data were analyzed, FR-β expression was 
observed in a greater percentage of cells in females 
than males, and the percentage of positively staining 
stromal cells was correlated with the cancer’s stage 
and lymph node involvement. Additionally, these data 
suggest that FR-β expression may be a useful indicator 
of a tumor’s metastatic potential and that the receptor 
might be exploited for folate-mediated drug targeting to 
certain cancers and their associated anti-inflammatory 
macrophages.
Figure 5: FR-β staining correlations. IHC was performed on a Asterand tissue microarray using the FR-β specific monoclonal 
antibody m909. The approximate percentage of positively staining cells within the tumor and stroma were determined. A) Statistically 
significant differences (p-value <0.05) using ANOVA or a t-test and correlations (p-value <0.05) using a Spearman correlation between 
the percentage of FR-β staining cells and various pathological data are summarized. B) Graphs for select FR-β staining and various 
pathological data (error bars represent SEM) are shown. Lymph node involvement was based upon the AJCC/UICC stage - TxNxMx. 
Additional graphs and data can be found in the Supporting Information.
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Table 1: Prevalence of FR-β expressing cancer and stromal cells in various human tumor sections.
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MATERIALS AND METHODS
Materials
Horseradish peroxidase (HRP)-streptavidin and EZ-
Link Sulfo-NHS-LC-Biotin were purchased from Thermo 
Scientific (Madison, WI). PeCy7-labeled streptavidin was 
obtained from eBioscience (San Diego, CA). RPMI1640 
was purchased from Life Technologies (Grand Island, NY) 
and fetal bovine serum (FBS) was from Hyclone (Novato, 
CA). The cancer tissue microarrays that were examined 
in this study were: i) a hepatocellular carcinoma tissue 
microarray from Emory University (Atlanta, GA), ii) 
a thymoma tissue microarray from Indiana University-
Purdue University Indianapolis (Indianapolis, IN), iii) 
a custom multi-tumor tissue microarray (TMA-00300) 
from Asterand (Detroit, MI), iv) a high density multiple 
organ tumor and normal tissue microarray (MC5003) 
from US Biomax (Rockville, MD), and v) a breast 
tumor microarray (ARY-HH0056), a brain glioma tumor 
microarray (ARY-HH0138) and an endometrial carcinoma 
progression tumor microarray (ARY-HH0211) from Folio 
Biosciences (Columbus, OH). Oregon green labeled folate 
was synthesized as previously described [36]. All other 
materials were purchased from VWR (Chicago, IL).
Antibody
A human monoclonal anti-human FR-β antibody 
(m909) was generated against the extracellular domain 
(23~236 aa) of human FR-β and has been characterized 
previously in human samples [24]. m909 was labeled 
with EZ-Link Sulfo-NHS-LC-Biotin according to 
manufacturer’s instructions. 
Flow cytometric analysis of the specificity of 
biotinylated-m909
CHO-β (human FR-β stably-transfected cell line 
generously provided by Dr. Manohar Ratnam), mock-
infected parental CHO-K1 cells, and KB cells (human 
FR-α highly-expressing cell line) were trypsinized, 
washed in PBS, and resuspended in folate-deficient 
RPMI1640 plus 1% FBS. Aliquots of cells were incubated 
with serial concentrations of biotinylated-m909 (~0.7 mg/
mL) or Oregon green labeled folate at 4°C for 1 hour. The 
cells then were washed once with ice-cold PBS and the 
antibody-labeled cells were stained with Streptavidin-
PeCy7 (1:100 dilution) at 4°C for 1 hour. Cells then were 
washed once with ice-cold PBS, resuspended in PBS + 1% 
FBS and analyzed by flow cytometry using a FACSCalibur 
(Beckton Dickinson, San Jose, CA). Flow cytometry data 
were analyzed using Flowjo (TreeStar, Ashland, OR).
Immunohistochemisty
All tumor microarrays had been previously fixed in 
formalin and embedded in paraffin by the provider. TMA 
samples were initially deparaffinized with 3 changes of 
xylene, rehydrated in a series of ethanol dilutions (100%, 
95%, then 70% ethanol) and rinsed well in running 
distilled water. Slides then were placed in a preheated 
DAKO Target Retrieval buffer for 40 min then cooled 
in the buffer for 20 min followed by a 5 min rinse in 
running distilled water. After the heat inactivated epitope 
retrieval step, sections were incubated with 3% H2O2 in 
ethanol for 5 min to inactivate the endogenous peroxides, 
followed by a protein blocking step for 5 min. Slides were 
rinsed well with Tris-buffered saline containing 0.05% 
Tween 20 (TBST) wash buffer and incubated for 30 min 
at room temperature with biotinylated-m909 (~0.7 mg/
mL). Sections then were rinsed with TBST wash buffer 
followed by the addition of HRP-streptavidin. After a 
10 min incubation at room temperature, the slides were 
washed with TBST. Finally, slides were incubated in 
3,3’-diaminobenzidine for 5 min at room temperature, 
counterstained with Modified Schmidts’s Hematoxylin 
for 5 min and rinsed in tap water for 3 min. The samples 
then were dehydrated through graded alcohols, cleared 
in 3 changes of xylene and mounted with a permanent 
mounting media. 
Statistics
Differences between groups were determined 
by either a t-test (assuming equal variance and 2-tails 
for all samples) for data sets with only 2 groups or a 
1-way ANOVA for data sets containing multiple groups. 
Correlation analyses were performed using a Spearman 
correlation analysis. Differences were considered 
statistically significant if the p-value was <0.05.
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